Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia.

J Hematol Oncol · 2022 · PMC9716776 · PMID 36457063

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Treatment with nanocarriers transporting FLT3-siRNA showed a clear trend toward longer survival, which with the numbers of animals used did not reach significance (Fig. 7 B).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.